DUBLIN--(BUSINESS WIRE)--The 'Global Irritable Bowel Disease Market (2024 Edition): Analysis By Drug Class (Corticosteroids, JAK inhibitors, TNF inhibitors, Other Drug Classes), By Route of Administration, By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)' report has been added to ResearchAndMarkets.com's offering..

都柏林--（商业新闻短讯）--“全球肠易激综合征市场（2024年版）：按药物类别（皮质类固醇、JAK抑制剂、TNF抑制剂、其他药物类别）、给药途径、适应症、地区、国家分析：市场洞察与预测（2019-2029）”报告已添加到ResearchAndMarkets.com的产品中。。

The Global Irritable Bowel Disease market showcased growth at a CAGR of 2.60% during 2019-2022. The market was valued at USD 21.45 Billion in 2022 which is expected to reach USD 27.16 Billion in 2029. The increasing incidence and prevalence of Crohn's Disease, and Ulcerative Colitis are major drivers for the growth of the Market..

2019-2022年，全球肠易激综合征市场的复合年增长率为2.60%。2022年市场价值214.5亿美元，预计2029年将达到271.6亿美元。克罗恩病和溃疡性结肠炎的发病率和患病率不断上升，是市场增长的主要驱动力。。

The report analyses the Irritable Bowel Disease Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).

该报告按地区（美洲、欧洲、亚太地区、中东和非洲）和10个国家（美国、加拿大、德国、英国、法国、意大利、西班牙、中国、日本、印度）分析了肠易激综合征市场。

The global IBD market has been steadily growing, driven by factors such as increasing incidence and prevalence of IBD worldwide. According to recent studies, the prevalence of IBD is rising globally, affecting millions of individuals across all age groups. This increasing prevalence has led to a surge in demand for effective treatments and diagnostics, thereby fueling market growth..

全球IBD市场一直在稳步增长，受全球IBD发病率和流行率增加等因素的驱动。根据最近的研究，IBD的患病率在全球范围内上升，影响了所有年龄段的数百万人。这种日益增长的流行率导致对有效治疗和诊断的需求激增，从而推动了市场的增长。。

The landscape of IBD treatment has undergone a paradigm shift with continuous therapeutic innovations. Biologic agents targeting specific inflammatory pathways have emerged as effective treatments for moderate to severe IBD, offering improved disease management and symptom control.

IBD治疗的前景随着不断的治疗创新而发生了范式转变。针对特定炎症途径的生物制剂已成为中重度IBD的有效治疗方法，可改善疾病管理和症状控制。

Moreover, personalized medicine approaches, driven by advancements in pharmacogenomics and precision medicine, are increasingly being explored to tailor treatments according to individual patient profiles. Furthermore, research into microbiome modulation and gut-targeted therapies holds promise for novel treatment modalities in the future..

此外，在药物基因组学和精准医学进步的推动下，越来越多地探索个性化医学方法，以根据个体患者的情况量身定制治疗方法。此外，对微生物组调节和肠道靶向治疗的研究有望在未来提供新的治疗方式。。

The global market for Irritable Bowel Disease is highly competitive, with numerous pharmaceutical companies and biotechnology firms competing for market share.

全球肠易激综合征市场竞争激烈，众多制药公司和生物技术公司争相抢占市场份额。

Scope of the Report

报告的范围

The report analyses the Irritable Bowel Disease Market by Value (USD Billion).

该报告按价值（十亿美元）分析了肠易激综合征市场。

The report analyses the Irritable Bowel Disease Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).

该报告按地区（美洲、欧洲、亚太地区、中东和非洲）和10个国家（美国、加拿大、德国、英国、法国、意大利、西班牙、中国、日本、印度）分析了肠易激综合征市场。

The report presents the analysis of Irritable Bowel Disease Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.

该报告分析了2019-2022年历史时期、2023年估计年份和2024-2029年预测期间的肠易激综合征市场。

The report analyses the Irritable Bowel Disease Market by Drug Class (Corticosteroids, JAK inhibitors, TNF inhibitors, Other Drug Classes)

该报告按药物类别（皮质类固醇、JAK抑制剂、TNF抑制剂、其他药物类别）分析了肠易激综合征市场

The report analyses the Irritable Bowel Disease Market By Route of Administration (Injectable, Oral).

该报告通过给药途径（注射，口服）分析了肠易激综合征市场。

The report analyses the Irritable Bowel Disease Market by Indication (Crohn's Disease, Ulcerative Colitis).

该报告通过适应症（克罗恩病，溃疡性结肠炎）分析了肠易激综合征市场。

The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Drug Classes, by Route of Administration & by Indication.

该报告的主要见解是通过SWOT和波特的五力分析框架提出的。此外，市场的吸引力已按地区，药物类别，给药途径和适应症呈现。

Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.

此外，报告还分析了该行业的主要机遇、趋势、驱动因素和挑战。

The report tracks competitive developments, strategies, mergers and acquisitions and new product development.

该报告跟踪竞争发展、战略、并购和新产品开发。

Strategic Recommendations

战略建议

Shift towards Small Molecule Therapies

转向小分子疗法

Diversification of Therapeutic Targets

治疗目标的多样化

Competitive Positioning

竞争定位

Companies' Product Positioning

公司的产品定位

Market Position Matrix

市场地位矩阵

Market Share Analysis of Irritable bowel disease Market

肠易激综合征市场份额分析

Company Profiles

公司简介

Johnson & Johnson

强生公司

Pfizer

辉瑞公司

Novartis AG

诺华

Eli Lilly and Company

礼来公司

AbbVie Inc.

AbbVie股份有限公司。

GSK Plc.

葛兰素史克股份有限公司。

UCB S.A

美国。

Takeda Pharmaceuticals

武田制药

Bristol-Myers Squibb Co.

百时美施贵宝公司。

Celltrion

细胞三酮

For more information about this report visit https://www.researchandmarkets.com/r/hradkj

有关此报告的更多信息，请访问https://www.researchandmarkets.com/r/hradkj

About ResearchAndMarkets.com

关于ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com是全球领先的国际市场研究报告和市场数据来源。我们为您提供有关国际和地区市场、关键行业、顶尖公司、新产品和最新趋势的最新数据。